Nyxoah is trading at $1.38, up 8.66%, with the move appearing mainly sector-driven. - Healthcare gained 1.27% as renewed biotech optimism, acquisition activity and a supportive regulatory backdrop improved sentiment. - No new company-specific announcement was identified for September 25, 2026; Nyxoah’s latest listed release concerns its September 21 CFO transition. - Recent clinical and BREATHE-study developments remain supportive background but do not directly explain today’s move.